MACROGENICS, INC. Debt Securities, Available-for-sale, Amortized Cost
MACROGENICS, INC. (MGNX) had Debt Securities, Available-for-sale, Amortized Cost of $59.41 million as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Notes › Credit Losses
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2026-08-14
- 2026-06-30: Debt Securities, Available-for-sale, Amortized Cost $59.41M.
- 2026-03-31: Debt Securities, Available-for-sale, Amortized Cost $87.74M.
- 2025-12-31: Debt Securities, Available-for-sale, Amortized Cost $132.66M.
- 2025-09-30: Debt Securities, Available-for-sale, Amortized Cost $66.26M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost |
|---|---|
| 2026-06-30 | $59.41M 10-Q · filed 2026-08-14 |
| 2026-03-31 | $87.74M 10-Q · filed 2026-05-13 |
| 2025-12-31 | $132.66M 10-Q · filed 2026-08-14 |
| 2025-09-30 | $66.26M 10-Q · filed 2025-11-12 |
| 2025-06-30 | $45.81M 10-Q · filed 2025-08-14 |
| 2025-03-31 | $8.57M 10-Q · filed 2025-05-13 |
| 2024-12-31 | $18.82M 10-K · filed 2026-03-09 |
| 2024-09-30 | $20.72M 10-Q · filed 2024-11-05 |
| 2024-06-30 | $56.46M 10-Q · filed 2024-08-06 |
| 2024-03-31 | $103.92M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $128.85M 10-K · filed 2025-03-20 |
| 2023-09-30 | $166.57M 10-Q · filed 2023-11-06 |
| 2023-06-30 | $131.66M 10-Q · filed 2023-08-09 |
| 2023-03-31 | $17.38M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $45.47M 10-K · filed 2024-03-07 |
| 2022-09-30 | $39.74M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $112.60M 10-Q · filed 2022-08-08 |
| 2022-03-31 | $136.94M 10-Q · filed 2022-05-03 |
| 2021-12-31 | $120.21M 10-K · filed 2023-03-15 |
| 2021-09-30 | $108.37M 10-Q · filed 2021-11-02 |
| 2021-06-30 | $108.34M 10-Q · filed 2021-07-29 |
| 2021-03-31 | $124.67M 10-Q · filed 2021-04-29 |
| 2020-12-31 | $91.41M 10-K · filed 2022-02-24 |
| 2020-09-30 | $79.02M 10-Q · filed 2020-11-04 |
| 2020-06-30 | $36.25M 10-Q · filed 2020-07-31 |
| 2020-03-31 | $77.72M 10-Q · filed 2020-05-05 |
| 2019-12-31 | $89.27M 10-K · filed 2021-02-25 |
| 2019-09-30 | $86.25M 10-Q · filed 2019-11-06 |
| 2019-06-30 | $91.79M 10-Q · filed 2019-07-31 |
| 2019-03-31 | $81.75M 10-Q · filed 2019-05-01 |
| 2018-09-30 | $58.34M 10-Q · filed 2018-11-07 |
| 2018-06-30 | $62.22M 10-Q · filed 2018-08-07 |
| 2018-03-31 | $59.66M 10-Q · filed 2018-05-07 |
| 2017-12-31 | $93.45M 10-K · filed 2019-02-26 |
| 2017-09-30 | $112.79M 10-Q · filed 2017-11-08 |
| 2017-06-30 | $127.11M 10-Q · filed 2017-08-02 |
| 2017-03-31 | $207.67M 10-Q · filed 2017-05-03 |
| 2016-12-31 | $200.97M 10-K · filed 2018-02-27 |
| 2016-09-30 | $204.21M 10-Q · filed 2016-11-02 |
| 2016-06-30 | $203.30M 10-Q · filed 2016-08-03 |
| 2016-03-31 | $152.44M 10-Q · filed 2016-05-04 |
| 2015-12-31 | $142.88M 10-K · filed 2017-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |